Our success depends on our ability to research and develop innovative healthcare products and make them accessible to as many people as possible.
We have a significant global presence with commercial operations in more than 150 countries, a network of 87 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China.
In 2016 we produced:
On 2 March 2015 we completed a 3-part transaction with Novartis which reshapes our business.
We acquired Novartis's vaccines business and combined our Consumer Healthcare businesses to create a new company. By substantially strengthening Vaccines and Consumer Healthcare, we can deliver far-reaching benefits to patients and consumers, and further value to shareholders. In addition, Novartis acquired our marketed Oncology portfolio.
View more about our global strategic priorities on our gsk.com.